» Articles » PMID: 28708470

Safety and Efficacy of an Absorbable Filter in the Inferior Vena Cava to Prevent Pulmonary Embolism in Swine

Overview
Journal Radiology
Specialty Radiology
Date 2017 Jul 15
PMID 28708470
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose To evaluate the immediate and long-term safety as well as thrombus-capturing efficacy for 5 weeks after implantation of an absorbable inferior vena cava (IVC) filter in a swine model. Materials and Methods This study was approved by the institutional animal care and use committee. Eleven absorbable IVC filters made from polydioxanone suture were deployed via a catheter in the IVC of 11 swine. Filters remained in situ for 2 weeks (n = 2), 5 weeks (n = 2), 12 weeks (n = 2), 24 weeks (n = 2), and 32 weeks (n = 3). Autologous thrombus was administered from below the filter in seven swine from 0 to 35 days after filter placement. Fluoroscopy and computed tomography follow-up was performed after filter deployment from weeks 1-6 (weekly), weeks 7-20 (biweekly), and weeks 21-32 (monthly). The infrarenal IVC, lungs, heart, liver, kidneys, and spleen were harvested at necropsy. Continuous variables were evaluated with a Student t test. Results There was no evidence of IVC thrombosis, device migration, caval penetration, or pulmonary embolism. Gross pathologic analysis showed gradual device resorption until 32 weeks after deployment. Histologic assessment demonstrated neointimal hyperplasia around the IVC filter within 2 weeks after IVC filter deployment with residual microscopic fragments of polydioxanone suture within the caval wall at 32 weeks. Each iatrogenic-administered thrombus was successfully captured by the filter until resorbed (range, 1-4 weeks). Conclusion An absorbable IVC filter can be safely deployed in swine and resorbs gradually over the 32-week testing period. The device is effective for the prevention of pulmonary embolism for at least 5 weeks after placement in swine. RSNA, 2017.

Citing Articles

Image-Guided Deployment and Monitoring of a Novel Tungsten Nanoparticle-Infused Radiopaque Absorbable Inferior Vena Cava Filter in a Swine Model.

San Valentin E, Damasco J, Bernardino M, Court K, Godin B, Canlas G J Vasc Interv Radiol. 2023; 35(1):113-121.e3.

PMID: 37696432 PMC: 10872373. DOI: 10.1016/j.jvir.2023.09.003.


The application of inferior vena cava filters in orthopaedics and current research advances.

He J, Wang Z, Zhou Y, Ni H, Sun X, Xue J Front Bioeng Biotechnol. 2022; 10:1045220.

PMID: 36479430 PMC: 9719953. DOI: 10.3389/fbioe.2022.1045220.


Nano-embedded medical devices and delivery systems in interventional radiology.

San Valentin E, Barcena A, Klusman C, Martin B, Melancon M Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022; 15(1):e1841.

PMID: 35946543 PMC: 9840652. DOI: 10.1002/wnan.1841.


Bismuth Nanoparticle and Polyhydroxybutyrate Coatings Enhance the Radiopacity of Absorbable Inferior Vena Cava Filters for Fluoroscopy-Guided Placement and Longitudinal Computed Tomography Monitoring in Pigs.

Damasco J, Huang S, Perez J, Manongdo J, Dixon K, Williams M ACS Biomater Sci Eng. 2022; 8(4):1676-1685.

PMID: 35343679 PMC: 9045416. DOI: 10.1021/acsbiomaterials.1c01449.


Optimization of the differentiation and quantification of high-Z nanoparticles incorporated in medical devices for CT-guided interventions.

Perez J, Jacobsen M, Damasco J, Melancon A, Huang S, Layman R Med Phys. 2020; 48(1):300-312.

PMID: 33216978 PMC: 8097741. DOI: 10.1002/mp.14601.


References
1.
Carlin A, Tyburski J, Wilson R, Steffes C . Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients. Arch Surg. 2002; 137(5):521-5; discussion 525-7. DOI: 10.1001/archsurg.137.5.521. View

2.
Singhana B, Chen A, Slattery P, Yazdi I, Qiao Y, Tasciotti E . Infusion of iodine-based contrast agents into poly(p-dioxanone) as a radiopaque resorbable IVC filter. J Mater Sci Mater Med. 2015; 26(3):124. PMC: 6154385. DOI: 10.1007/s10856-015-5460-0. View

3.
Muntz J, Michota F . Prevention and management of venous thromboembolism in the surgical patient: options by surgery type and individual patient risk factors. Am J Surg. 2010; 199(1 Suppl):S11-20. DOI: 10.1016/j.amjsurg.2009.10.007. View

4.
Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P . A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998; 338(7):409-15. DOI: 10.1056/NEJM199802123380701. View

5.
. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005; 112(3):416-22. DOI: 10.1161/CIRCULATIONAHA.104.512834. View